The board really has been asleep at the wheel. One wonders if they should take this unlisted. Dunno, you mentioned the Netherlands and Philips. Ironically, as an Old Minnett client, I last week received a presentation and term sheet for a maximum $15M raise for an unlisted medical AI company called Nicolab who have a strategic partnership with Philips and was founded by two Dutch clinicians in Amsterdam. They have a good chunk of the $15M already corner-stoned at a valuation of $135M. The raise will give them three years runway and they probably never have to list. They are targeting an aggressive expansion over the next few years with Philips in the US and Asia. They also partnered with Titan Neurosciences here in Australia and are the front runner for a $20M Federal Govt grant in 2024. There are lots of grants available in med tech and HMD needs to start getting some big grant wins.
There are significant advantages in being unlisted which leads into the question, would HMD be far better off doing a $10M rights issue (so you can choose to be diluted or not) to give them two years runway and then delisting off the asx? It seems like a lot of damage has been done as a listed ASX company and that damage is not easily reversed. What's the point of small regular raises on the ASX which is just kicking the can down the road? They raise small and then they're cum raise within six months. It's a vicious cycle and the board has a lot to answer for.
HMD Price at posting:
4.0¢ Sentiment: None Disclosure: Held
(20min delay)